- Home
- TRIB vs MTVA Comparison
TRIB vs MTVA Comparison
Compare TRIB & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- MTVA
- Stock Information
- Founded
- TRIB 1992
- MTVA 2014
- Country
- TRIB Ireland
- MTVA United States
- Employees
- TRIB N/A
- MTVA N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MTVA
- Sector
- TRIB Health Care
- MTVA
- Exchange
- TRIB Nasdaq
- MTVA NYSE
- Market Cap
- TRIB 13.0M
- MTVA 14.3M
- IPO Year
- TRIB N/A
- MTVA N/A
- Fundamental
- Price
- TRIB $0.67
- MTVA $0.64
- Analyst Decision
- TRIB
- MTVA Strong Buy
- Analyst Count
- TRIB 0
- MTVA 2
- Target Price
- TRIB N/A
- MTVA $7.50
- AVG Volume (30 Days)
- TRIB 2.4M
- MTVA 142.2K
- Earning Date
- TRIB 08-13-2025
- MTVA 08-13-2025
- Dividend Yield
- TRIB N/A
- MTVA N/A
- EPS Growth
- TRIB N/A
- MTVA N/A
- EPS
- TRIB N/A
- MTVA N/A
- Revenue
- TRIB $61,555,000.00
- MTVA N/A
- Revenue This Year
- TRIB $13.51
- MTVA N/A
- Revenue Next Year
- TRIB $13.14
- MTVA N/A
- P/E Ratio
- TRIB N/A
- MTVA N/A
- Revenue Growth
- TRIB 8.31
- MTVA N/A
- 52 Week Low
- TRIB $0.48
- MTVA $0.63
- 52 Week High
- TRIB $3.44
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- TRIB 48.68
- MTVA N/A
- Support Level
- TRIB $0.60
- MTVA N/A
- Resistance Level
- TRIB $0.87
- MTVA N/A
- Average True Range (ATR)
- TRIB 0.08
- MTVA 0.00
- MACD
- TRIB 0.01
- MTVA 0.00
- Stochastic Oscillator
- TRIB 33.94
- MTVA 0.00
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.